GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

General Biologicals 4117.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

8.15

-6.32%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About General Biologicals

Its shares trade on Taipei Exchange under the ticker 4117.TWO. It has been listed since 4 July 2002. In the fiscal year to 31 December 2025, it reported revenue of TWD 215.7m and net income of TWD 465.8m. At that date it held total assets of TWD 4.87bn and shareholders' equity of TWD 870.7m.

General Biologicals Corp. engages in research, development, manufacture and trade of diagnostics and pharmaceutical. The company is headquartered in Baoshan, Hsinchu. The company went IPO on 2002-07-04. The firm's main products include detection reagents, biological protein new drug, P113, and medical supplies. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
4 Jul 2002
Employees
63
Website
gbc.com.tw ↗

Leadership

Pay as last reported

  • Mr. Tsong Chin LinChairman of the Board, since 1989TWD 1.8m
  • Mr. Frank LinGeneral Manager, Director, since 2013
  • Ms. Cherie LinDeputy General Manager
  • Jinmei ShiHead of Finance & Accounting
  • Ms. Pi-Hua ChenDirector
  • Mr. Min Chih HsuanDirector
  • Mr. Che Ren ChuangIndependent Director
  • Xusong GuoIndependent Director
  • Ms. Cheryl LinIndependent Director
  • Mr. Jen-Leih WuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • General Biologicals Corp. has 63 employees focused on diagnostics and pharmaceutical research.
  • The company's main products include detection reagents and P113 for medical use.
  • Baoshan, Hsinchu serves as the headquarters for manufacturing and trade operations.

Weaknesses

  • The company's domestic market presence is limited to Baoshan, Hsinchu region.
  • General Biologicals Corp. lacks international distribution beyond overseas markets.
  • The firm's product range is restricted to diagnostics and pharmaceuticals only.

Opportunities

  • Expanding into the Health Care sector in Taiwan for new market growth.
  • Increasing demand for P113 in the Biotechnology industry globally.
  • Growing opportunities in the Information Technology sector for diagnostics.

Threats

  • Competition from other Health Care companies in Taiwan.
  • Regulatory challenges in the Biotechnology industry for new drugs.
  • Economic downturns affecting the Financials sector in Taiwan.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.